Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Selected Types Of Advanced Or Metastatic Cancer
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically diagnosed advanced (unresectable) or metastatic cancer with at least one measurable lesion as per RECIST 1.1 2) Women of childbearing potential must use adequate birth control for the duration of study participation and for 5 months after last dose of study Drug (Nivolumab) 3) Patients with advanced or metastatic melanoma who have progressed while receiving an anti-PD-1 or anti-PD-L1 antibody or within 3 months of discontinuation
You may not be eligible for this study if the following are true:
-
Individuals who meet any of the following criteria are ineligible for this study: 1) Prior treatment with iCPI, which is defined as an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways (Note: this criterion does not apply to patients with melanoma.) 2) History of life-threatening toxicity related to prior immune therapy (e.g., anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (e.g., hypo/hyperthyroidism).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.